Pages that link to "Q39635628"
Jump to navigation
Jump to search
The following pages link to Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. (Q39635628):
Displaying 44 items.
- Major clinical research advances in gynecologic cancer in 2016: 10-year special edition (Q33563963) (← links)
- Human papillomavirus vaccination: the population impact (Q33806566) (← links)
- Progress in prophylactic human papillomavirus (HPV) vaccination in 2016: A literature review (Q38628399) (← links)
- Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part I. (Q38639401) (← links)
- Serious adverse events after HPV vaccination: a critical review of randomized trials and post-marketing case series. (Q38668821) (← links)
- Vaccine-preventable anal human papillomavirus in Australian gay and bisexual men. (Q38673353) (← links)
- Cervical cancer screening in the era of HPV vaccination: A review of shifting paradigms in cytopathology (Q38673879) (← links)
- Pre-clinical and clinical development of the first placental malaria vaccine (Q38691920) (← links)
- Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice (Q40116011) (← links)
- Age of Acquiring Causal Human Papillomavirus (HPV) Infections: Leveraging Simulation Models to Explore the Natural History of HPV-induced Cervical Cancer (Q40191017) (← links)
- Age of human papillomavirus vaccination? (Q40669277) (← links)
- Natural History of HPV Infection across the Lifespan: Role of Viral Latency (Q41932990) (← links)
- Structure-Activity Relationship Studies of Pyrimido[5,4-b]indoles as Selective Toll-Like Receptor 4 Ligands (Q46091295) (← links)
- Identification of Biologically Active Pyrimido[5,4-b]indoles That Prolong NF-κB Activation without Intrinsic Activity. (Q46360938) (← links)
- Ten-year immune persistence and safety of the HPV-16/18 AS04-adjuvanted vaccine in females vaccinated at 15-55 years of age. (Q46515269) (← links)
- Immunological Tolerance, Pregnancy, and Preeclampsia: The Roles of Semen Microbes and the Father (Q47550799) (← links)
- Recognizing Gynecological Cancer in Primary Care: Risk Factors, Red Flags, and Referrals. (Q51743129) (← links)
- Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice. (Q52312756) (← links)
- The safety of Cervarix? - Authors' reply. (Q53620530) (← links)
- Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. (Q54217505) (← links)
- Opportunities and challenges for human papillomavirus vaccination in cancer. (Q54263650) (← links)
- HPV vaccination in male physicians: A survey of gynecologists and otolaryngology surgeons' attitudes towards vaccination in themselves and their patients. (Q55284158) (← links)
- Human Papillomavirus and Oropharyngeal Cancer Among Indigenous Australians: Protocol for a Prevalence Study of Oral-Related Human Papillomavirus and Cost-Effectiveness of Prevention. (Q55385410) (← links)
- Trial watch: DNA-based vaccines for oncological indications (Q56893452) (← links)
- Making HPV vaccination available to girls everywhere (Q57167626) (← links)
- Human papillomavirus vaccination coverage in Luxembourg – Implications of lowering and restricting target age groups (Q58026841) (← links)
- Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus (Q59329445) (← links)
- Human papillomavirus-associated oropharyngeal cancer: review of current evidence and management (Q64091019) (← links)
- Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine (Q64240435) (← links)
- The safety of Cervarix? (Q89026479) (← links)
- VIVIANE study of HPV vaccination (Q91541816) (← links)
- VIVIANE study of HPV vaccination - Authors' reply (Q91541823) (← links)
- A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years (Q91576754) (← links)
- Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV-16/18 antibodies (Q91627395) (← links)
- The effectiveness of vaccination to prevent the papillomavirus infection: a systematic review and meta-analysis (Q91818565) (← links)
- Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial (Q91874433) (← links)
- The situation of vaccines for the prevention of infections in adults: An opinion paper on the situation in Spain (Q92178995) (← links)
- Gynecological Cancers-the Changing Paradigm (Q92861685) (← links)
- Prevalence and genotype-specific distribution of human papillomavirus in Burundi according to HIV status and urban or rural residence and its implications for control (Q93013656) (← links)
- Reduction of cervical cancer incidence within a primary HPV screening pilot project (WOLPHSCREEN) in Wolfsburg, Germany (Q93112009) (← links)
- Personalized Human Papillomavirus Vaccination for Persistence of Immunity for Cervical Cancer Prevention: A Critical Review With Experts' Opinions (Q94546953) (← links)
- Measuring vaccine effectiveness against persistent HPV infections: a comparison of different statistical approaches (Q97526303) (← links)
- Evidence of HPV vaccination efficacy comes from more than clinical trials (Q97565439) (← links)
- Spotlight on the role of human papillomavirus vaccines (Q99563763) (← links)